17-7-5 ⓔ文献
Klastersky J: Febrile neutropenia. Curr Opin Oncol, 1993; 5: 625–632.
日本臨床腫瘍学会編：発熱性好中球減少症 (FN) の診療ガイドライン 改訂第2版，南江堂，2017.
Klastersky J, Paesmans M, et al: The multinational association for supportive care in cancer risk index: a multinational scoring system for identifying low–risk febrile neutropenic cancer patients. J Clin Oncol, 2000; 16: 3038–3051.
Lee A, Mirrett S, et al: Detection of bloodstream infections in adults: How many blood cultures are needed? J Clin Microbiol, 2007; 45: 3546–3548.
Koumakis G, Vassilomanolakis M, et al: Optimal timing (Preemptive versus supportive) of granulocyte colony–stimulating factor administration following high–dose cyclophosphamide. Oncology, 1999; 56: 28–35.
日本癌治療学会編：G–CSF適正使用ガイドライン 2013年度版 Ver.5，金原出版，2018.
日本癌治療学会編：制吐薬適正使用ガイドライン 第2版 ver.2.2，金原出版，2018.
Saito M, Aogi K, et al: Palonosetron plus dexamethasone versus granisetron plus dexamethasone for prevention of nausea and vomiting during chemotherapy: a double–blind, double–dummy, randomised, comparative phase III trial. Lancet Oncol, 2009; 10: 115–124.
Hesketh PJ, Grunberg SM, et al: The oral neurokinin–1 antagonist aprepitant for the prevention of chemotherapy–induced nausea and vomiting: a multinational, randomized, double–blind, placebo–controlled trial in patients receiving high–dose cisplatin–the Aprepitant Protocol 052 Study Group. J Clin Oncol, 2003; 21: 4112–4119.
Hashimoto H, Abe M, et al: Olanzapine 5 mg plus standard antiemetic therapy for the prevention of chemotherapy–induced nausea and vomiting (J–FORCE): a multicentre, randomised, double–blind, placebo–controlled, phase 3 trial. Lancet Oncol, 2019; pii: S1470–2045 (19) 30678–3.